Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 54, Issue 21, Pages 1935-1945Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2009.05.074
Keywords
sex; antiplatelet agents; clopidogrel; randomized trial; cardiovascular disease
Categories
Funding
- American Heart Association [0775074]
- AstraZeneca
- Bristol-Myers Squibb
- Eisai
- Ethicon
- Heartscape
- Sanofi-Aventis
- Medicines Company
- Accumetrics
- GlaxoSmithKline
- Intekrin Therapeutics
- Merck
- Merck/Schering-Plough Partnership
- Novartis
- Takeda
- Roche
- DSI
- Eli Lilly
- Schering-Plough
- Thrombovision
- Helena
- Haemoscope
- Corgenix/Aspirin Works
- Eli Lilly/Daiichi Sankyo
- Medical Research Council [MC_U137686851] Funding Source: researchfish
- MRC [MC_U137686851] Funding Source: UKRI
Ask authors/readers for more resources
Objectives This study sought to investigate the efficacy and safety of clopidogrel in women and men. Background Previous analyses have shown sex-based differences in response to several antiplatelet medications. Little is known about the efficacy and safety of clopidogrel in women and men. Methods This study performed a meta-analysis of all blinded randomized clinical trials comparing clopidogrel and placebo (CURE [Clopidogrel in Unstable Angina to Prevent Recurrent Events], CREDO [Clopidogrel for the Reduction of Events During Observation], CLARITY-TIMI 28 [Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis In Myocardial Infarction 28], COMMIT [Clopidogrel and Metoprolol in Myocardial Infarction Trial], and CHARISMA [Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance] trials), involving a total of 79,613 patients, of whom 30% were women. The relative efficacy and safety of clopidogrel at reducing cardiovascular events (cardiovascular death, myocardial infarction [MI], or stroke) in women and men was estimated using random-effects modeling. Results Overall, clopidogrel was associated with a highly significant 14% proportional reduction in the risk of cardiovascular events (odds ratio [OR]: 0.86; 95% confidence interval [CI]: 0.80 to 0.93), with no significant differences in treatment effect between women and men. Among the 23,533 women enrolled, there were fewer cardiovascular events in the clopidogrel group compared with the placebo group (11.0% vs. 11.8%; OR: 0.93; 95% CI: 0.86 to 1.01). In women the risk reduction with clopidogrel seemed to be greatest for MI (OR: 0.81; 95% CI: 0.70 to 0.93), with the effects on stroke (OR: 0.91; 95% CI: 0.69 to 1.21) or total death (OR: 0.99; 95% CI: 0.90 to 1.08) not statistically significant. Among the 56,091 men enrolled, there were fewer cardiovascular events in those receiving clopidogrel compared with placebo (7.8% vs. 9.0%; OR: 0.84; 95% CI: 0.78 to 0.91), and the risk reduction was significant for MI (OR: 0.83; 95% CI: 0.76 to 0.92), stroke (OR: 0.83; 95% CI: 0.71 to 0.96), and total death (OR: 0.91; 95% CI: 0.84 to 0.97). Clopidogrel increased the risk of major bleeding in both women (OR: 1.43; 95% CI: 1.15 to 1.79) and men (OR: 1.22; 95% CI: 1.05 to 1.42). Conclusions Clopidogrel reduces the risk of cardiovascular events in both women and men. (J Am Coll Cardiol 2009; 54: 1935-45) (C) 2009 by the American College of Cardiology Foundation
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available